Harri Järveläinen
@hulivili.bsky.social
Biotech entrepreneur. Toxicologist. Economist. Plus a veterinarian! Obsessed with taking the coolest science into clinical PoC.
Here's some of the evidence supporting muscarinic M1 receptor activation (not M4!) to potential therapeutic effects in two core domains of schizophrenia: positive symptoms and cognitive impairment.
November 21, 2024 at 10:59 PM
Here's some of the evidence supporting muscarinic M1 receptor activation (not M4!) to potential therapeutic effects in two core domains of schizophrenia: positive symptoms and cognitive impairment.